Accelerating Timelines and Reducing Cost in Early Clinical Drug Development
In person exclusive panel and networking evening
Early phase drug development requires both speed and flexibility - however when it comes to clinical manufacturing, innovation often collides with operational realities
While pharmaceutical and biotech companies strive to accelerate timelines, many factors remain beyond their control. The process itself is growing increasingly complex, impacted by raw material shortages, process variability, and differing expectations around compliance, technology transfer, and risk tolerance.
In this panel discussion, industry experts will explore some of the critical challenges in drug development and share strategies to overcome delays and minimise risks, covering topics such as:
- Key pain points across the development process and how they differ for large pharmaceutical companies vs. small biotechs
- Advantages of an integrated CRO/CDMO model, including earlier submissions, stability testing, and improved clinical data quality through flexible formulations
- How an end-to-end approach to formulation development and optimisation for both small molecules and biologics can reduce costs and accelerate timelines
- The value of partnering with a global expert to advance compounds efficiently through early clinical development
Speakers
Rosario Lobrutto
Vice President, Global Head of Technical Operations
Ironwood Pharmaceuticals
Enjoy the Evening
5:30pm – 6pm
Arrival & Networking
(Drinks & Hors d ’Oeuvres will be served)
6pm – 7pm
Panel Discussion
7pm - 8pm
Post Panel Networking Drinks
(further Hors d ’Oeuvres and sweet treats)
GETTING THERE
(only 10 min walk from conference venue)
Frankfurt Marriott Hotel
This private event is being held in the Gold Room on the First Floor
